Methotrexaat Focus (Methotrexate)

Methotrexate blocks the enzyme dihydrofolate reductase, which is essential for producing tetrahydrofolate, a co‑factor needed for synthesizing purines and pyrimidines. By limiting these building blocks, the drug reduces DNA, RNA and protein synthesis, especially in rapidly dividing cells such as cancer cells and activated immune cells, thereby exerting antineoplastic and immunosuppressive effects.

The dose of Methotrexaat Focus is individualized and must be prescribed by a qualified healthcare professional. Dosing depends on the specific indication, patient weight, renal and hepatic function, and response to therapy. Physicians determine the appropriate amount and schedule, and patients should follow the prescribed regimen exactly.

Methotrexaat Focus is classified as Pregnancy Category X, meaning it is contraindicated in pregnancy because it can cause fetal harm. Women of child‑bearing potential must use effective contraception. Breastfeeding is also not recommended, as methotrexate is excreted in milk and may affect the infant.

To order Methotrexaat Focus, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and necessary import documentation.

Methotrexaat Focus belongs to the antimetabolite class, offering a non‑biologic option for diseases like rheumatoid arthritis and certain cancers. Compared with biologic agents, methotrexate is generally less expensive and administered subcutaneously, but may require more intensive laboratory monitoring. In oncology, it is often combined with other chemotherapeutics to enhance efficacy.

Methotrexaat Focus should be stored at ambient temperature, below 25 °C, in its original packaging to protect it from moisture and direct sunlight. Keep the product out of reach of children and avoid freezing. No special refrigeration is required for this subcutaneous formulation.

Methotrexaat Focus is given by subcutaneous injection, typically into the abdomen, thigh or upper arm. Healthcare professionals should follow aseptic technique, use the appropriate needle size, and rotate injection sites to minimize local irritation. Patients may be taught self‑injection after proper training and assessment.

The most serious risks include severe bone marrow suppression leading to pancytopenia, significant liver toxicity such as fibrosis or cirrhosis, and pulmonary complications like interstitial pneumonitis. These adverse events require prompt medical attention and regular monitoring of blood counts, liver enzymes and respiratory status.

Methotrexaat Focus should not be used by individuals who are pregnant, have known hypersensitivity to methotrexate, suffer from severe hepatic disease, have uncontrolled infections, or have significant bone marrow disorders. Patients with impaired renal function may need dose adjustments, and the decision to use the drug must be made by a qualified clinician.